SurModics Stock News

Surmodics, Inc. (NASDAQ:SRDX) Director David Dantzker sold 3,475 shares of Surmodics stock in a transaction on Wednesday, November 24th. The stock was sold at an average price of $47.01, for a total transaction of $163,359.75. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Shares of SRDX []

Surmodics (NASDAQ:SRDX) issued an update on its FY 2022 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $-1.750-$-1.250 for the period, compared to the Thomson Reuters consensus estimate of $0.920. The company issued revenue guidance of $97 million-$101 million, compared to the consensus revenue estimate of $118.12 million. Shares []

Surmodics (NASDAQ:SRDX) updated its FY 2022 earnings guidance on Wednesday. The company provided earnings per share guidance of $-1.750-$-1.250 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.920. The company issued revenue guidance of $97 million-$101 million, compared to the consensus revenue estimate of $118.12 million. Separately, Needham & []

Related Stocks: SRDX ,

Millennium Management LLC boosted its position in Surmodics, Inc. (NASDAQ:SRDX) by 113.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 107,421 shares of the companys stock after buying an additional 56,977 shares during the period. Millennium Management LLC owned approximately 0.77% []

Surmodics (NASDAQ:SRDX) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Analyst Ratings This is a breakdown of recent ratings and recommmendations for Surmodics and Inovio Pharmaceuticals, []

Surmodics (NASDAQ:SRDX) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. Profitability This table compares Surmodics and LENSARs net margins, return on equity and return on assets. Net []

Surmodics' (SRDX) fiscal fourth-quarter results reflect benefits from segmental strength.

Surmodics' (SRDX) CEO Gary Maharaj on Q4 2021 Results - Earnings Call Transcript

Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics Announces Successful First Patient Uses of Sublime™ Radial Access .018 RX PTA Dilatation Catheter

HRC vs. SRDX: Which Stock Is the Better Value Option?

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q3 2021 Results - Earnings Call Transcript

Higher revenues from the IVD segment drives Surmodics' (SRDX) fiscal third-quarter top line.

SurModics (SRDX) delivered earnings and revenue surprises of -54.55% and -0.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?